De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

IN8bio Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van IN8bio is gedaald met een gemiddeld jaarlijks tempo van -35.5%, terwijl de winst van de sector Biotechs jaarlijks groeide met 19.7%.

Belangrijke informatie

-35.5%

Groei van de winst

45.4%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	n/a
Rendement op eigen vermogen	-234.6%
Nettomarge	n/a
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Opbrengsten en kosten

Hoe IN8bio geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGM:INAB Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	-32	14	18
31 Mar 24	-31	14	17
31 Dec 23	-30	14	17
30 Sep 23	-30	14	16
30 Jun 23	-30	14	17
31 Mar 23	-30	14	16
31 Dec 22	-29	14	14
30 Sep 22	-27	14	13
30 Jun 22	-23	13	10
31 Mar 22	-18	10	8
31 Dec 21	-15	7	7
30 Sep 21	-12	5	6
30 Jun 21	-11	4	6
31 Mar 21	-11	4	6
31 Dec 20	-10	3	5
30 Sep 20	-9	3	5
30 Jun 20	-8	3	4
31 Mar 20	-6	3	3
31 Dec 19	-6	3	2

Kwaliteitswinsten: INAB is momenteel verliesgevend.

Groeiende winstmarge: INAB is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: INAB is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 35.5% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van INAB over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: INAB is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 0.5% ).

Rendement op eigen vermogen

Hoge ROE: INAB heeft een negatief Return on Equity ( -234.62% ), omdat het momenteel verliesgevend is.

IN8bio Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Recent updates

IN8bio, Inc. announced that it expects to receive $12.405547 million in funding

IN8bio, Inc. Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio, Inc. Announces Updated Positive Clinical Data from Both of the Phase 1 Investigator-Sponsored Trials of INB-100 for Hematological Malignancies and INB-200 for GBM

IN8bio (NASDAQ:INAB) Will Have To Spend Its Cash Wisely

IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio, Inc. Presents Progression-Free Survival Update from Phase 1 Study of INB-200 At 2024 American Society of Clinical Oncology Annual Meeting

In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024

In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc., Annual General Meeting, Jun 12, 2024

IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate

New major risk - Financial position

IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

IN8bio, Inc. announced that it has received $14.442298 million in funding from Bios Equity Partners LP

New major risk - Shareholder dilution

Price target decreased by 16% to US$11.00

IN8bio, Inc. Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

IN8bio, Inc. Appoints Corinne Epperly to the Board of Directors

IN8bio, Inc.’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

IN8bio, Inc. Presents Biologic Correlative Data from the Inb-200 Phase 1 Trial in Newly Diagnosed Glioblastoma At the Society for Immunotherapy of Cancer's 38Th Annual Meeting

IN8bio, Inc. Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Companies Like IN8bio (NASDAQ:INAB) Could Be Quite Risky

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc. Announces Presentations at the Society for Immunology of Cancer 38th Annual Meeting

IN8bio, Inc. Announces Updated Data from the Ongoing Phase 1 Clinical Trial of Inb-200 in Patients with Newly Diagnosed Glioblastoma Multiforme

IN8bio, Inc. Announces Positive Preclinical Data Underscoring the Potential of Its DeltEx Gamma-Delta T Cells to Target and Kill Ovarian Cancer

Is IN8bio (NASDAQ:INAB) In A Good Position To Invest In Growth?

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

In8bio Announces New Data At Ash Showing 100% of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of Inb-100

IN8bio Announces FDA Clearance to Initiate A Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma

Price target decreased to US$9.67

High number of new and inexperienced directors

IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting

High number of new and inexperienced directors

Here's Why We're Watching IN8bio's (NASDAQ:INAB) Cash Burn Situation

High number of new and inexperienced directors

IN8bio, Inc. Appoints Michael R. Bishop to Its Scientific Advisory Board

IN8bio gains 53% as H.C. Wainwright initiates with Buy

Independent Director recently bought US$200k worth of stock

IN8bio raises additional funds from underwriter of stock offering

IN8bio prices $10.25M stock offering

IN8bio, Inc. Provides Clinical Update from Ongoing Phase 1 Trial of INB-100

IN8bio, Inc. Appoints Kenneth R. Lamontagne as Senior Vice President, Business Development

IN8bio, Inc. Announces Positive Glioblastoma Multiforme (Gbm) Clinical Updates from the INB-200 Phase 1 Trial Presented At Asco 2022

We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate

IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform

IN8bio, Inc., Annual General Meeting, Jun 01, 2022

IN8bio, Inc. Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100

IN8bio (NASDAQ:INAB) Is In A Good Position To Deliver On Growth Plans

IN8bio, Inc. Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme

In8bio Provides Update from the Ongoing Phase 1 Clinical Trial of Its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

IN8bio, Inc. Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

Director recently bought US$1.0m worth of stock

IPO Update: IN8bio Aims For Downsized IPO

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden